skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Mild Toxicity and Favorable Prognosis of High-Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients With Early-Stage Nasal NK/T-Cell Lymphoma

Abstract

Purpose: The value of intensity-modulated radiotherapy (IMRT) for early-stage nasal NK/T-cell lymphoma has not been previously reported. The aim of the present study was to assess the dosimetric parameters, toxicity, and treatment outcomes of patients with nasal NK/T-cell lymphoma. Methods and Materials: Between 2003 and 2008, 42 patients with early-stage nasal NK/T-cell lymphoma underwent definitive high-dose and extended involved-field IMRT with or without combination chemotherapy. The median radiation dose to the primary tumor was 50 Gy. The dose-volume histograms of the target volume and critical normal structures were evaluated in all patients. The locoregional control, overall survival, and progression-free survival were calculated using the Kaplan-Meier method. Results: The average mean dose delivered to the planning target volume was 55.5 Gy. Only 1.3% and 2.5% of the planning target volume received <90% and 95% of the prescribed dose, respectively, indicating excellent planning target volume coverage. The mean dose and average dose to the parotid glands was 15 Gy and 14 Gy, respectively. With a median follow-up time of 27 months, the 2-year locoregional control, overall survival, and progression-free survivalrate was 93%, 78%, and 74%, respectively. No Grade 4 or 5 acute or late toxicity was reported. Conclusions: High-dose and extended involved-fieldmore » IMRT for patients with early-stage nasal NK/T-cell lymphoma showed favorable locoregional control, overall survival, and progression-free survival, with mild toxicity. The dose constraints of IMRT for the parotid glands can be limited to <20 Gy in these patients.« less

Authors:
 [1];  [2];  [1]; ; ; ; ; ; ; ; ; ; ; ;  [1]
  1. Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (China)
  2. (China)
Publication Date:
OSTI Identifier:
22056100
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 82; Journal Issue: 3; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHEMOTHERAPY; GLANDS; LYMPHOMAS; NOSE; PATIENTS; PLANNING; RADIATION DOSES; RADIOTHERAPY; TOXICITY

Citation Formats

Wang Hua, Department of Radiation Oncology, Cancer Hospital of Jiangxi Province, Jiangxi Province, Li Yexiong, E-mail: yexiong@yahoo.com, Wang Weihu, Jin Jing, Dai Jianrong, Wang Shulian, Liu Yueping, Song Yongwen, Wang Zhaoyang, Liu Qingfeng, Fang Hui, Qi Shunan, Liu Xinfan, and Yu Zihao. Mild Toxicity and Favorable Prognosis of High-Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients With Early-Stage Nasal NK/T-Cell Lymphoma. United States: N. p., 2012. Web. doi:10.1016/J.IJROBP.2011.02.039.
Wang Hua, Department of Radiation Oncology, Cancer Hospital of Jiangxi Province, Jiangxi Province, Li Yexiong, E-mail: yexiong@yahoo.com, Wang Weihu, Jin Jing, Dai Jianrong, Wang Shulian, Liu Yueping, Song Yongwen, Wang Zhaoyang, Liu Qingfeng, Fang Hui, Qi Shunan, Liu Xinfan, & Yu Zihao. Mild Toxicity and Favorable Prognosis of High-Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients With Early-Stage Nasal NK/T-Cell Lymphoma. United States. doi:10.1016/J.IJROBP.2011.02.039.
Wang Hua, Department of Radiation Oncology, Cancer Hospital of Jiangxi Province, Jiangxi Province, Li Yexiong, E-mail: yexiong@yahoo.com, Wang Weihu, Jin Jing, Dai Jianrong, Wang Shulian, Liu Yueping, Song Yongwen, Wang Zhaoyang, Liu Qingfeng, Fang Hui, Qi Shunan, Liu Xinfan, and Yu Zihao. Thu . "Mild Toxicity and Favorable Prognosis of High-Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients With Early-Stage Nasal NK/T-Cell Lymphoma". United States. doi:10.1016/J.IJROBP.2011.02.039.
@article{osti_22056100,
title = {Mild Toxicity and Favorable Prognosis of High-Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients With Early-Stage Nasal NK/T-Cell Lymphoma},
author = {Wang Hua and Department of Radiation Oncology, Cancer Hospital of Jiangxi Province, Jiangxi Province and Li Yexiong, E-mail: yexiong@yahoo.com and Wang Weihu and Jin Jing and Dai Jianrong and Wang Shulian and Liu Yueping and Song Yongwen and Wang Zhaoyang and Liu Qingfeng and Fang Hui and Qi Shunan and Liu Xinfan and Yu Zihao},
abstractNote = {Purpose: The value of intensity-modulated radiotherapy (IMRT) for early-stage nasal NK/T-cell lymphoma has not been previously reported. The aim of the present study was to assess the dosimetric parameters, toxicity, and treatment outcomes of patients with nasal NK/T-cell lymphoma. Methods and Materials: Between 2003 and 2008, 42 patients with early-stage nasal NK/T-cell lymphoma underwent definitive high-dose and extended involved-field IMRT with or without combination chemotherapy. The median radiation dose to the primary tumor was 50 Gy. The dose-volume histograms of the target volume and critical normal structures were evaluated in all patients. The locoregional control, overall survival, and progression-free survival were calculated using the Kaplan-Meier method. Results: The average mean dose delivered to the planning target volume was 55.5 Gy. Only 1.3% and 2.5% of the planning target volume received <90% and 95% of the prescribed dose, respectively, indicating excellent planning target volume coverage. The mean dose and average dose to the parotid glands was 15 Gy and 14 Gy, respectively. With a median follow-up time of 27 months, the 2-year locoregional control, overall survival, and progression-free survivalrate was 93%, 78%, and 74%, respectively. No Grade 4 or 5 acute or late toxicity was reported. Conclusions: High-dose and extended involved-field IMRT for patients with early-stage nasal NK/T-cell lymphoma showed favorable locoregional control, overall survival, and progression-free survival, with mild toxicity. The dose constraints of IMRT for the parotid glands can be limited to <20 Gy in these patients.},
doi = {10.1016/J.IJROBP.2011.02.039},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 82,
place = {United States},
year = {2012},
month = {3}
}